Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from a phase I trial investigating the anti-PD-1 monoclonal antibody nivolumab.
Mario Sznol, MD, a professor of medical oncology at the Yale Cancer Center in New Haven, Connecticut, discusses the long-term follow-up results from a phase I trial investigating the anti-PD-1 monoclonal antibody nivolumab.
In patients with previously treated melanoma, overall survival was 16.8 months, which compares well to other agents, Sznol suggests. Objective response rates were 31% with a median duration of response around 2 years, which are very high numbers, Sznol notes.
Nivolumab is a very well tolerated drug, Sznol says. The rates of grade 3/4 adverse events (AEs) were 14% with 5% experiencing select immune-related AEs. Only 6% of patients discontinued treatment due to toxicity. Pneumonitis caused concerns in earlier trials; however, proper side effect management prevented it from occurring.
Additional activity was observed in several patients outside of those classified by RECIST criteria. A prolongation in stable disease was observed in 11% of patients with 4 patients experiencing unconventional responses, characterized by tumor growth followed by shrinkage. These data will ultimately be reflected in the survival curve in the future phase III trial.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More